EUVIMEDEUVIMED entdecken
Open Access

Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease

Robert Przybylski iD, Logan M Eberly, Mark E Alexander iD, Vassilios J Bezzerides, Elizabeth S DeWitt, Audrey Dionne, Douglas Y Mah iD, John K Triedman, Edward P Walsh, Edward T O'Leary iD

Journal of Cardiovascular Electrophysiology · 2023-12 · 34 (12) · 2545-2551

DOI: 10.1111/jce.16095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 17.10.2023. Verfasst von Robert Przybylski und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Tachycardia, Supraventricular, Atrial Flutter, Heart Defects, Congenital. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra‐atrial reentrant tachycardia (IART) is well‐described in adults without congenital heart disease (CHD). Data are sparse regarding their use for the same purpose in adults with CHD and in adolescent patients with anatomically normal hearts and we sought to describe the use of class IC drugs in this population and identify factors associated with decreased likelihood of success.

Methods

Single center retrospective cohort study of patients who received oral flecainide or propafenone for medical cardioversion of AF or IART from 2000 to 2022. The unit of analysis was each episode of AF/IART. We performed a time‐to‐sinus rhythm analysis using a Cox proportional hazards model clustering on the patient to identify factors associated with increased likelihood of success.

Results

We identified 45 episodes involving 41 patients. As only episodes of AF were successfully cardioverted with medical therapy, episodes of IART were excluded from our analyses. Use of flecainide was the only factor associated with increased likelihood of success. There was a statistically insignificant trend toward decreased likelihood of success in patients with CHD.

Conclusions

Flecainide was more effective than propafenone. We did not detect a difference in rate of conversion to sinus rhythm between patients with and without CHD and were likely underpowered to do so, however, there was a trend toward decreased likelihood of success in patients with CHD. That said, medical therapy was effective in >50% of patients with CHD with AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationTachycardia, SupraventricularAtrial FlutterHeart Defects, CongenitalAdultAdolescentHumansAnti-Arrhythmia AgentsFlecainidePropafenoneElectric CountershockRetrospective StudiesTachycardia

Stichwörter der Autor:innen

adult congenital heart diseaseatrial fibrillationflecainideintra-atrial reentrant tachycardiapropafenone

Substanzen

Anti-Arrhythmia AgentsFlecainidePropafenone

Autor:innen und Institutionen

  • Department of Cardiology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Robert Przybylski, Mark E Alexander, Douglas Y Mah, Edward T O'Leary

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Przybylski, R., Eberly, L. M., Alexander, M. E., Bezzerides, V. J., DeWitt, E. S., Dionne, A., Mah, D. Y., Triedman, J. K., Walsh, E. P., & O'Leary, E. T. (2023). Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. Journal of Cardiovascular Electrophysiology, 34(12), 2545-2551. https://doi.org/10.1111/jce.16095

Vancouver

Przybylski R, Eberly LM, Alexander ME, Bezzerides VJ, DeWitt ES, Dionne A, et al. Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. Journal of Cardiovascular Electrophysiology. 2023;34(12):2545-2551. doi:10.1111/jce.16095

BibTeX
@article{Przybylski2023,
  author = {Przybylski, Robert and Eberly, Logan M and Alexander, Mark E and Bezzerides, Vassilios J and DeWitt, Elizabeth S and Dionne, Audrey and Mah, Douglas Y and Triedman, John K and Walsh, Edward P and O'Leary, Edward T},
  title = {Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2023},
  volume = {34},
  number = {12},
  pages = {2545--2551},
  doi = {10.1111/jce.16095}
}
Kostenlos starten →